Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

J
James Tisdale

Primary Investigator

Overview

The purpose of this study is to determine the effectiveness of progesterone given by mouth for minimizing drug EKG response to a drug.

Description

Our objective is to evaluate and compare the efficacy of novel therapeutic approaches to reduce the risk of drug-induced QTc interval prolongation and TdP.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Torsades de pointes,menopause,healthy,Torsades de pointe
  • Age: Between 21 Years - 100 Years
  • Gender: Female

Inclusion Criteria
Postmenopausal women, based on the following criteria:
Age 50 years of age or older AND
No menstrual periods for 365 days or longer
 
Premenopausal women:
21-40 years of age
 
Exclusion Criteria
History of breast, ovarian or uterine cancer
Taking hormone replacement therapy
Heart failure due to reduced ejection fraction (left ventricular ejection fraction 40%)
Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death
Concomitant use of any QT interval prolonging drug
Permanently paced ventricular rhythm
Additional Information:
Participants will be paid for their participation.

Updated on 04 Mar 2024. Study ID: 1806935117

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center